1. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Issue 10374 (4th February 2023) Authors: Swen, Jesse J; van der Wouden, Cathelijne H; Manson, Lisanne EN; Abdullah-Koolmees, Heshu; Blagec, Kathrin; Blagus, Tanja; Böhringer, Stefan; Cambon-Thomsen, Anne; Cecchin, Erika; Cheung, Ka-Chun; Deneer, Vera HM; Dupui, Mathilde; Ingelman-Sundberg, Magnus; Jonsson, Siv; Joefield-Roka, Candace; J... Journal: Lancet Issue: Volume 401:Issue 10374(2023) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10236 (16th May 2020) Authors: Galsky, Matthew D; Arija, José Ángel Arranz; Bamias, Aristotelis; Davis, Ian D; De Santis, Maria; Kikuchi, Eiji; Garcia-del-Muro, Xavier; De Giorgi, Ugo; Mencinger, Marina; Izumi, Kouji; Panni, Stefano; Gumus, Mahmut; Özgüroğlu, Mustafa; Kalebasty, Arash Rezazadeh; Park, Se Hoon; Alekseev, Boris;... Journal: Lancet Issue: Volume 395:Issue 10236(2020) Page Start: 1547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting. (2020) Authors: KOVAČ, ANJA; Matos, Erika; Kuhar, Cvetka Grašič; Čakš, Marina; Ovčariček, Tanja; Mencinger, Marina; Humar, Mojca; Borštnar, Simona Journal: Cancer treatment and research communications Issue: Number 25(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗